Variation in adherence to management guidelines for inflammatory bowel disease (IBD) suggests variable quality of care. Furthermore, evidence suggests variation in patient outcomes by geography, race, type and experience of provider.
Quality indicators (QIs) have been developed to measure the structure, processes, and outcomes of health care delivery, and can be used to measure improvement over time. In IBD, several societies and groups have publicized quality indicators. Important outcome measures for IBD include rates of unplanned care, hospitalization, corticosteroid and narcotic use, health-related quality of life and symptoms.
Traditional methods for quality improvement can and have been applied to IBD. Efforts to improve care require sustained, iterative changes over time. Several examples exist of single-center efforts to improve processes of care. A quality improvement network has used the Model for Improvement to demonstrate improvement in patient outcomes over time including unplanned care and other outcomes. A pediatric improvement network has demonstrated improved remission rates over time. Quality of care for IBD can be measured and improved.
Gil Y. Melmed, MD, Co-Director, IBD Center, Professor of Medicine, Cedars-Sinai Medical Center
Gil Y. Melmed, MD, MS, is the Co-Director of the Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center in Los Angeles, California. He earned his medical degree from Albert Einstein College of Medicine in the Bronx, New York, and master of science in clinical research from UCLA School of Medicine, Los Angeles. He completed his gastroenterology fellowship at the University of California, Los Angeles.
Dr Melmed has authored or coauthored more than 150 articles in peer-reviewed journals and several book chapters. Dr Melmed has served as Associate Editor of the American Journal of Gastroenterology, an ad hoc reviewer for several journals, and clinical research editor for Inflammatory Bowel Disease. His research interests include clinical outcomes and quality of care in IBD, as well as translational prognostic and therapeutic strategies to improve inflammation and clinical outcomes. He has lectured nationally and internationally on various topics related to inflammatory bowel disease. He is a current or past committee member of several professional organizations, including the American Gastroenterology Association, American College of Gastroenterology and the Crohn’s and Colitis Foundation, where he serves as co-chair of the IBD Quality of Care committee. He has led or participated in the development of quality indicators for IBD with the American Gastroenterology Association, the Crohn’s and Colitis Foundation, the National Quality Forum, and the Canadian Crohn’s and Colitis organizations.Message Presenter
(Moderator) Kenneth W Gaither, PhD, Vice President, Medical Imaging, Bioclinica
Dr. Gaither has global responsibility leading the implementation and scientific oversight of clinical trials for Bioclinica and has more than 25 years of experience in the field. His areas of focus includes bone densitometry, body composition assessment, vertebral fracture and morphology methods, structural geometry of bone, and semi-quantitative assessments of video endoscopy within international multicenter clinical trials. He has published on these areas in peer-reviewed journals, and is a member of the American Society for Bone and Mineral Research, International Society for Clinical Densitometry and the European Crohn’s and Colitis Organisation. Dr. Gaither received his Ph.D. in systems science with a focus on the utilization of simulation modeling for risk based systems. He has held vice president level positions within project management, data management, site selection and operations in a variety of healthcare industries including clinical research organizations, centralized imaging laboratories, and medical device manufacturers.Message Presenter
Who Should Attend?
- Medical Professionals (Nurses and Study Coordinators)
- Medical Directors from Pharma and CROs
- Contracting professionals from Pharna and CROs
- Program and Operational Directors and Managers from Pharma and CROs
What You Will Learn
- What is quality of care?
- What constitutes high quality care for IBD? how is it defined?
- What are opportunities to improve care for IBD?
- How can quality of care be improved, and what examples are there for QI in IBD?
Bioclinica is a global, life-science provider that utilizes science and technology to reduce risk of clinical trials – helping companies to develop new, life-improving therapies more efficiently and safely. The company’s offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance, and trial management.